External quality assessment for EGFR mutations in Italy: improvements in performances over the time
- PMID: 29181190
- PMCID: PMC5699165
- DOI: 10.1136/esmoopen-2017-000160
External quality assessment for EGFR mutations in Italy: improvements in performances over the time
Abstract
External quality assessment (EQA) schemes are essential procedures to assess the quality level of laboratories performing molecular testing of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology (SIAPEC-IAP) organise EGFR EQA programmes to ensure that the Italian laboratories achieve the quality standard levels required. Comparing the 2011, 2013 and 2015 EGFR EQA schemes, it was possible to observe improvements in the methodologies used and the outcomes. The use of direct sequencing was reduced from 78.7% in 2011 to only 14.1% in 2015, whereas the use of pyrosequencing and real-time PCR increased. The number of rounds in which centres using direct sequencing failed was significantly higher than the number of rounds that failed using other methods, both when analysing each single scheme and when combining the three EQAs together. In 2011 and 2013, about 29% of the participants failed the first phase of the programmes, compared with the 13% of centres failing in 2015, suggesting that the switch to more sensitive and robust methods could allow to increase the percentage of good performers. Although the molecular analyses are performed with good quality in Italy, the continuous education carried out by AIOM and SIAPEC-IAP remains a fundamental tool to maintain this quality level.
Keywords: EGFR mutations; External Quality Assessment; Non-Small Cell Lung Cancer; molecular testing.
Conflict of interest statement
Competing interests: None declared.
Figures


Similar articles
-
The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.J Transl Med. 2015 Sep 3;13:287. doi: 10.1186/s12967-015-0655-1. J Transl Med. 2015. PMID: 26335936 Free PMC article.
-
Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.J Thorac Oncol. 2013 Jun;8(6):773-8. doi: 10.1097/JTO.0b013e31828c2b08. J Thorac Oncol. 2013. PMID: 23575414
-
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.PLoS One. 2011;6(12):e29146. doi: 10.1371/journal.pone.0029146. Epub 2011 Dec 21. PLoS One. 2011. PMID: 22216189 Free PMC article.
-
The external quality assessment schemes in Thailand.Rinsho Byori. 2002 Feb;50(2):121-5. Rinsho Byori. 2002. PMID: 11925846 Review.
-
European consensus conference for external quality assessment in molecular pathology.Ann Oncol. 2013 Aug;24(8):1958-63. doi: 10.1093/annonc/mdt153. Epub 2013 Apr 23. Ann Oncol. 2013. PMID: 23613479 Review.
Cited by
-
Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys.Virchows Arch. 2021 May;478(5):995-1006. doi: 10.1007/s00428-020-02966-7. Epub 2020 Nov 23. Virchows Arch. 2021. PMID: 33225398 Free PMC article.
-
Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers.Diagnostics (Basel). 2020 Oct 18;10(10):837. doi: 10.3390/diagnostics10100837. Diagnostics (Basel). 2020. PMID: 33080995 Free PMC article.
-
Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.BMC Cancer. 2020 May 1;20(1):366. doi: 10.1186/s12885-020-06831-3. BMC Cancer. 2020. PMID: 32357863 Free PMC article.
-
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.Cancers (Basel). 2019 Sep 25;11(10):1431. doi: 10.3390/cancers11101431. Cancers (Basel). 2019. PMID: 31557965 Free PMC article.
-
Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL.Virchows Arch. 2021 Mar;478(3):553-565. doi: 10.1007/s00428-020-02928-z. Epub 2020 Oct 13. Virchows Arch. 2021. PMID: 33047156 Free PMC article. Review.
References
-
- Mitsudomi T, Morita S, Yatabe Y, et al. . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8. 10.1016/S1470-2045(09)70364-X - DOI - PubMed
-
- Rosell R, Carcereny E, Gervais R, et al. . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous